REYKJAVIK, Iceland, Dec. 6 /PRNewswire-FirstCall/ -- deCODE genetics today announced that it has named Dr. Linda Buck to join its Board of Directors, effective immediately. Dr. Buck, who received a Nobel Prize in physiology or medicine in 2004 for her discoveries on the workings of the olfactory system, is Associate Director of the Basic Sciences Division at Fred Hutchinson Cancer Research Center in Seattle and is a Howard Hughes Medical Institute investigator. She also is an affiliate professor of physiology and biophysics at the University of Washington.
"It is a great pleasure to welcome Linda to our board," said Kari Stefansson, CEO of deCODE. "Linda is recognized around the world as a pioneer in utilizing molecular biology for discovering a new understanding of complex biological systems, expertise that I believe will enable her to make a valuable contribution to our efforts to apply human genetics to make better medicine. As a former colleague I know how fortunate we are to have a scientist and person of Linda's distinction join our board, and we look forward to working with her," Stefansson said.
Dr. Buck is the author of numerous scientific publications and the recipient of many honors and awards for her research. Prior to her current positions, Dr. Buck was a professor of neurobiology at Harvard Medical School. Dr. Buck holds BS degrees in psychology and microbiology from the University of Washington, and she received her PhD in immunology from the University of Texas Southwestern Medical Center at Dallas.
About deCODE
deCODE genetics is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at http://www.decode.com.
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
deCODE geneticsCONTACT: Edward Farmer, +1-212-343-2819, info@decode.is, or Joy Bessenger,+1-212-481-3891, ir@decode.is, both of deCODE
Web site: http://www.decode.com/
